Wiciński, M.; Wódkiewicz, E.; Górski, K.; Walczak, M.; Malinowski, B.
Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury. Pharmaceuticals 2020, 13, 379.
https://doi.org/10.3390/ph13110379
AMA Style
Wiciński M, Wódkiewicz E, Górski K, Walczak M, Malinowski B.
Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury. Pharmaceuticals. 2020; 13(11):379.
https://doi.org/10.3390/ph13110379
Chicago/Turabian Style
Wiciński, Michał, Eryk Wódkiewicz, Karol Górski, Maciej Walczak, and Bartosz Malinowski.
2020. "Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury" Pharmaceuticals 13, no. 11: 379.
https://doi.org/10.3390/ph13110379
APA Style
Wiciński, M., Wódkiewicz, E., Górski, K., Walczak, M., & Malinowski, B.
(2020). Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury. Pharmaceuticals, 13(11), 379.
https://doi.org/10.3390/ph13110379